News

CUTISS receives new patent for skin engineering technology

CUTISS has been granted a new U.S. patent. It covers automated methods and systems for producing skin grafts, including the separation of skin layers and the isolation of key cell types from a skin biopsy. The patented invention relates to a broader automated workflow for skin graft production, in which a...

read more

Lightium Selects Aras Innovator to Support Development of Photonic AI Chips

ANDOVER, Mass.--(BUSINESS WIRE)--Aras, a leading provider of digital thread solutions for product lifecycle management (PLM) and engineering AI, today announced that Lightium, a Switzerland-based startup specializing in photonic integrated circuits (PICs), has selected Aras Innovator® to establish a connected foundation for managing the complexity of its photonic chip development. Lightium selected Aras Innovator...

read more

Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced corporate...

read more

Repertoire Immune Medicines Announces FDA Fast Track Designation for its Investigational Immune Medicine, RPTR-1-201 Repertoire Immune Medicines

CAMBRIDGE, Mass., May 7, 2026 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to RPTR-1-201 for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic triple-negative breast...

read more

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth

Schlieren (Zurich), Switzerland, May 7, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced the appointment of I.V. Hall as Chief Operating Officer effective June 1, 2026. I.V. will succeed Sjoerd Musters, who will conclude his role as the current Chief Operating...

read more